Surgical Management and Outcomes in Patients with Cushing Disease with Negative Pituitary Magnetic Resonance Imaging

• Published in: World neurosurgery 2012-03, Vol.77 (3), p.525-532
• Main Authors: Yamada, Shozo, Fukuhara, Noriaki, Nishioka, Hiroshi, Takeshita, Akira, Inoshita, Naoko, Ito, Junko, Takeuchi, Yasuhiro
• Format: Article
• Language: English
• Subjects: Adrenocorticotropic Hormone - blood; Adult; Aged; Child; Corticotropin-Releasing Hormone - blood; Cushing disease; Female; Follow-Up Studies; Humans; Hypophysectomy; Immunohistochemistry; Long-term outcome; Magnetic Resonance Imaging; Male; Microadenoma; Middle Aged; Muscle Weakness - etiology; Neoplasm Recurrence, Local; Neurosurgery; Normal magnetic resonance imaging; Obesity - etiology; Petrosal Sinus Sampling; Pituitary ACTH Hypersecretion - pathology; Pituitary ACTH Hypersecretion - surgery; Pituitary Gland - pathology; Pituitary Neoplasms - complications; Pituitary Neoplasms - pathology; Postoperative Complications - epidemiology; Retrospective Studies; Transsphenoidal surgery; Young Adult
• ISSN: 1878-8750; 1878-8769
• DOI: 10.1016/j.wneu.2011.06.033

Objective To analyze our experience with transsphenoidal surgery (TSS) in patients with Cushing disease (CD) with no visible adenoma on magnetic resonance imaging (MRI). Methods Between January 1988 and October 2010, 183 patients with CD underwent TSS at Toranomon Hospital. We retrospectively analyzed data in 18 patients without visible adenomas on MRI and compared them with 106 patients with microadenomas. Results Of 106 patients with MRI-visible microadenomas, postoperative remission was achieved in 104 patients (98.1%) and recurrence of CD was observed in 4 patients (3.8%) during a mean follow-up of 5.2 years. Of the 18 patients with negative MRI, postoperative remission was achieved in 0 of the 3 patients with negative inferior petrosal sinus sampling (IPSS), in 50% of those with positive IPSS (7 of 14 patients), and in 1 patient with inconclusive IPSS. No disease recurrence has been observed during a mean follow-up of 3.3 years in the 8 patients with remission, and no tumor has emerged on MRI in 10 patients with failed surgery during a mean follow-up of 4.2 years. No major perioperative complications, including hypopituitarism, occurred in this series. Conclusions When the pituitary origin of adrenocorticotropic hormone secretion is established by IPSS in patients with normal MRI findings, we recommend TSS as the first-line treatment for CD, although chance of surgical cure (50% in this series) is lower than that of MRI-visible microadenomas. In contrast, other therapeutic options must be considered in patients with negative MRI and IPSS findings.